P785 The prevalence of inflammatory bowel disease doubled in the last decade in Israel: an epiIIRN national population-based study

Friedman, M.; Navon, Dan; Asayag, N; Focht, Gili; Brufman, Ilan; Feldman, Becca; Cahan, Amos; Ledderman, Natan; Matz, Eran; Chowers, Yehuda; Eliakim, Rami; Ben‐Horin, Shomron; Odes, Shmuel; Schwartz, Doron; Dotan, Iris; Israeli, Eran; Balicer, Ran D.; Turner, Dan

doi:10.1093/ecco-jcc/jjy222.909

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 1089 subjects (725 subjects in the control group and 364 subjects in the AD group, applying 2:1 ratio between groups) were estimated to enable a power of 80% and 5% type I error, to detect a difference of 2% in the prevalence of subjects with IBD between the AD and the control groups, assuming a prevalence of subjects with IBD of 2.4% for patients with AD and 0.4% in the control groups, respectively. These assumptions were based on an estimated 0.4% prevalence of IBD in Israel, 31 and a large Israeli database study 32 that found an overall 1.7% prevalence of IBD in AD, increasing for patients with severe AD to 3.1% (data not published). Approximately 70% of patients in our specialized AD clinic have moderate‐to‐severe AD, so we applied an estimated IBD prevalence of 2.4%.…”

Section: Methodsmentioning

confidence: 99%

The association between atopic dermatitis and inflammatory bowel disease in adults: A cross‐sectional study in a specialized atopic dermatitis clinic

Rom,

Snir,

Schwartz

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) and inflammatory bowel disease (IBD) share genetic susceptibility loci with immune regulation functions. Atopic dermatitis was associated with IBD mostly in database studies.ObjectiveTo assess whether AD is associated with an increased prevalence of IBD in a tertiary dermatology clinic.MethodsA retrospective cross‐sectional analysis using medical records of adults with verified AD followed up at an AD clinic, compared with age‐ and sex‐matched (1:2) controls from the general dermatology clinic in the same hospital.ResultsOverall, 9/364 (2.47%) of patients with AD had verified IBD, compared with 7/725 (0.97%) of controls (p = 0.0512). In multivariable logistic regression adjusting for age, gender and smoking, the association became significant (adjusted OR = 3.89, 95% CI: 1.28–11.85). Stratified for AD severity, only moderate‐to‐severe AD was associated with IBD (p = 0.035), with an adjusted OR of 4.45 (95% CI: 1.43–13.90). Mild AD was not associated with IBD, but the study was not powered for this sub‐analysis. In the AD group, older age was associated with IBD (p = 0.0172).ConclusionThis study, in a robustly verified cohort of patients, supports an association between AD, especially the moderate‐to‐severe forms, and IBD. A multidisciplinary approach for patients with moderate‐to‐severe AD should extend to consider IBD.

show abstract

Section: Methodsmentioning

confidence: 99%

The association between atopic dermatitis and inflammatory bowel disease in adults: A cross‐sectional study in a specialized atopic dermatitis clinic

Rom,

Snir,

Schwartz

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic gastrointestinal disorders affecting an estimated 1.5 million Americans, 2.2 million people in Europe, and several hundred thousand more worldwide 1 . In Israel, IBD incidence was reported to be 18.2 per 100 000 persons in 2016 and the prevalence of CD was 312.84 per 100 000 persons in the country's Jewish population 2 . In general, treatment of CD is complex and may include the use of 5‐aminosalicylates (5‐ASA), corticosteroids (CS), methotrexate, and other immunomodulators (IM), as well as biologic therapies.…”

Section: Introductionmentioning

confidence: 99%

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis

et al. 2022

View full text Add to dashboard Cite

Background and Aim In 2017, ustekinumab (UST) was included in Israel's National Basket of Health Services for treatment of biologic‐experienced Crohn's disease (CD) patients with moderately to severely active disease. This study aims to provide real‐world evidence on persistence and clinical outcomes among early users of UST. Methods This retrospective cohort study was conducted using data from Maccabi Healthcare Services (MHS; 2.5‐million‐member state‐mandated health provider, Israel). Adult patients with a CD diagnosis code who had ≥1 dispensed UST prescription in 2017–2018 and at least 12 months of prior continuous health plan enrollment were included. Outcomes, including treatment discontinuation, dose‐escalation (based on shortened intervals between purchases), CD‐related surgery, CD‐related hospitalization, corticosteroid (CS) discontinuation, and use of opioids were evaluated from the date of first dispensed UST through the end of 2019 using Kaplan–Meier analysis. Results A total of 162 eligible patients (81 [49.4%] female; median age 34.4 years [IQR 23.2–46.3]; median years since CD diagnosis 8.6 [IQR 4·8–16.0]) were enrolled in the study. Discontinuation rate after 365 and 540 days of follow‐up was 27.8% and 35.6%. Dose escalation was estimated at 15.4% and 28.6%, respectively. The first‐year cumulative rate of CD‐related surgery and CD‐related hospitalization were estimated at 4.7% and 9.8%, respectively. Conclusion In this real‐world CD cohort of UST users, results suggest persistence is relatively high as compared to other biologics for CD. Comparative effectiveness of different biologic treatments for CD in this population should be further explored.

show abstract

“…The incidence and prevalence of pediatric CD has increased worldwide over the last decades (5,6). In Israel, the incidence of inflammatory bowel disease (IBD) has increased significantly in the last 15 years especially in the pediatric population (7,8).…”

mentioning

confidence: 99%

Long‐Term Follow‐up and Predictors of Complicated Disease Behavior in Pediatric Crohn's Disease Patients

Kori

Avidan²,

Topf-Olivestone³

2021

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Objective:Identifying predictors of inflammatory bowel disease (IBD) outcome in order to optimize individual patient management in has become an important goal. We aimed to describe the long-term outcome of pediatric Crohn disease (CD) patients and identify risk factors for complicated behavior.Methods:Pediatric CD patients diagnosed between 1998 and 2014, with long-term follow-up were included. Baseline data; age, gender, weight/height/BMI percentiles, and family history of IBD. Disease characteristics (Paris classification), laboratory testing, imaging and treatment were documented. Outcome data; evidence of stricturing or penetrating disease, hospitalizations, surgical intervention, malignancies, and mortality.Results:Of 93 patients included, mean age at diagnosis 13.5 (±3.2), 51 (55%) male, median follow-up 10.3 years (±4 SD(. Disease location at diagnosis: 29 (31.2%) distal ileum, 17 (18.3%) colonic, 40 (43.0%) ileo-colonic. Seven (7.5%) had upper gastrointestinal and 36 (38.7%) perianal involvement. Behavior at diagnosis, 68 (73.1%) inflammatory (B1), and 25 (26.9%) complicated [(B2 (stricturing) and/or B3 (penetrating)]. Twenty (23.2%) of B1 evolved to B2 and/or B3, thus by the end of follow-up 45 (48.4%) had complicated behavior. Sixty-seven (72%) were hospitalized, 20 (21.5%) underwent surgery, two developed malignancy with no mortalities. In a logistic regression model, growth delay (hazard ratio [HR], 5.02 [1.10–22.85], P = 0.037) and low albumin levels (HR, 3.97 [1.32–11.97], P = 0.014) at diagnosis were predictors of complicated disease in adulthood.Conclusions:Over a quarter of pediatric Crohn disease patients present with complicated behavior. During follow-up another quarter progress to complicated disease behavior. Delayed growth and low albumin at diagnosis predict progression.

show abstract

P785 The prevalence of inflammatory bowel disease doubled in the last decade in Israel: an epiIIRN national population-based study

Cited by 4 publications

References 0 publications

The association between atopic dermatitis and inflammatory bowel disease in adults: A cross‐sectional study in a specialized atopic dermatitis clinic

The association between atopic dermatitis and inflammatory bowel disease in adults: A cross‐sectional study in a specialized atopic dermatitis clinic

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis

Long‐Term Follow‐up and Predictors of Complicated Disease Behavior in Pediatric Crohn's Disease Patients

Contact Info

Product

Resources

About